The Non-Hodgkin Lymphoma (NHL) market was impacted by relapsed /refractory Non-Hodgkin Lymphoma (NHL), Follicular Lymphoma (FL), Diffuse large B-cell lymphoma (DLBCL), and Marginal Zone Lymphoma (MZL) data presented during the American Society of Clinical Oncology (ASCO) meeting in Chicago, IL.

Breaking Data worked with 30 oncologists during the meeting to better understand the commercial implications of data presented for REVLIMID® (lenalidomide), POLIVY® (polatuzumab vedotin), CALQUENCE® (acalabrutinib), KEYTRUDA® (pembrolizumab), MOR208, umbralisib, ME-401, and mosunetuzumab.

Companies presenting data included: AstraZeneca, Celgene, Genentech, MEI Pharma, Morphosys, and TG Therapeutics.

Get immediate access to this 61-slide report so you can make better decisions today and prepare for tomorrow.

Non-Hodgkin lymphoma Report ASCO 2019

American Society of Clinical Oncology

Chicago, IL
May 31 to Jun 4

Share: